This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

BROSSARD, Quebec, Sept. 03, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence ( ), announces a non-brokered private placement (“Private placement”) of 10 units (each a “Unit”) to be issued at a price of $10,000 per Unit for gross proceeds of $100,000.

Each Unit consists of: (i) One $10,000 unsecured convertible debenture (each a “Debenture”), and (ii) 10,000 stock warrants (each a “Warrant”).

Eac

See Full Page